Peng Yuan

10PUBLICATIONS
0CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Apr 15, 2025
Genetic associations of plasma proteins and breast cancer identify potential therapeutic drug candidates.

Liuliu Quan, Xin Luo, Chenxu Meng

|Jan 07, 2024
Prognostic factors and benefit populations of ovarian function suppression in premenopausal HR+/HER2+ early-stage breast cancer patients who received trastuzumab: Evidence from a real-world study with long-term follow-up.

Jie Ju, Song-Lin Gao, Jia-Yu Wang

|May 05, 2023
Combined chemo-endocrine therapy as a potential new option for HR+/HER2- advanced breast cancer: a prospective study of fulvestrant plus oral vinorelbine.

Xue Wang, Jian Yue, Yikun Kang

|Mar 02, 2023
Association between homologous recombination deficiency and outcomes with platinum and platinum-free chemotherapy in patients with triple-negative breast cancer.

Yimeng Chen, Xue Wang, Feng Du

|Dec 05, 2022
Prognostic factors and adjuvant systemic therapy for patients with HER2-positive T1N0 breast cancer: evidence from a real-world study with long-term follow-up.

Song-Lin Gao, Ding-Yuan Wang, Xi Wang

|Jun 14, 2022
Combined analysis of receptor expression reflects inter-and intra-tumor heterogeneity in HR+/HER2+ breast cancer.

Jie Ju, Feng Du, Song-Lin Gao

Pageof 2

Frequent Collaborators